Patents by Inventor Roger John Butlin
Roger John Butlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100173958Abstract: Compounds of formula (I), or salts thereof, which inhibit acetyl CoA(acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, wherein, for example, R1 is optionally substituted phenyl or naphthyl; Ring A is selected from (3-6C)cycloalkyl, (5-12C)bicycloalkyl and phenyl; n is 0, 1 or 2; R2 is, for example, hydrogen, fluoro, chloro or hydroxy; Ring B is selected from (3-6C)cycloalkyl, (5-12C)bicycloalkyl and phenyl; L1 is a direct bond or a defined linker group and R3 is, for example, hydroxy, carboxy or (1-6C)alkoxycarbonyl; together with processes for their preparation, pharmaceutical compositions containing them and their use as medicaments.Type: ApplicationFiled: June 8, 2007Publication date: July 8, 2010Inventors: Stuart Norman Lile Bennett, Roger John Butlin, Alleyn Thomas Plowright
-
Publication number: 20100094010Abstract: Processes for preparing compounds of Formula I and IV are described.Type: ApplicationFiled: October 16, 2009Publication date: April 15, 2010Applicant: AstraZeneca ABInventors: Margaret Anne Butlin, Roger John Butlin, Philip John Hogan, Andreas Meudt
-
Publication number: 20100093757Abstract: A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.Type: ApplicationFiled: August 4, 2009Publication date: April 15, 2010Applicant: AstraZeneca ABInventors: Stuart Norman Lile BENNETT, Roger John Butlin, Leonie Campbell, Robert Darren Morse Davies, Graeme Richard Robb, Rolf Peter Walker, Michael James Waring, Helen Claire Pointon, Mikael Dan Brink, Jonas Rickard Fägerhag, Ulrik Jurva, Volker Schnecke, Anette Marie Svensson Henriksson, Christer Ralf Westerlund, Peter Gustaf Bonn
-
Publication number: 20090298853Abstract: DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is ?O; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct bond or —O—; Y2 is —(CH2)r— wherein r is 2 or 3; n is 0 or n is 1 when Y1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or —O—; p is 0, 1 or 2 and when p is 1 or 2 RA1 and RA2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.Type: ApplicationFiled: December 19, 2008Publication date: December 3, 2009Applicant: AstraZeneca ABInventors: Udo Andreas Bauer, Jonas Gunnar Barlind, Petra Johannesson, Jan Magnus Johansson, Alexander Tobias Noeske, Annika Ulrika Petersson, Alan Martin Birch, Roger John Butlin, Clive Green, Andrew Leach, Ragnar Hovland
-
Patent number: 7626020Abstract: The invention relates to compounds such as where P is a nitrogen-protecting group, and to processes for preparing these compounds.Type: GrantFiled: February 17, 2005Date of Patent: December 1, 2009Assignee: AstraZeneca ABInventors: Margaret Anne Butlin, Roger John Butlin, Philip John Hogan, Andreas Meudt
-
Publication number: 20090275620Abstract: Compounds of formula (I), or salts thereof, which inhibit acetyl CoA (acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, wherein R1, R2 and R3 are each independently selected from hydrogen, fluoro, chloro, cyano, trifluoromethyl, trifluoromethoxy and difluoromethoxy; together with processes for their preparation, pharmaceutical compositions containing them and their use as medicaments.Type: ApplicationFiled: May 29, 2007Publication date: November 5, 2009Inventors: Roger John Butlin, Alleyn Thomas Plowright
-
Publication number: 20090215779Abstract: Compounds of Formula (I): wherein R1-R2, W and Y are as described in the specification, and their salts and pro-drugs, are inhibitors of DGAT and are thereby useful in the treatment of, for example, obesity. Processes for preparing compounds of formula (I) are also described.Type: ApplicationFiled: June 6, 2006Publication date: August 27, 2009Inventors: Roger John Butlin, Clive Philip Green, William McCoull
-
Publication number: 20090209602Abstract: Compounds of formula (I), or salts thereof, which inhibit acetyl CoA(acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, wherein, for example, R1 is an optionally substituted aryl or optionally substituted heteroaryl group, Y is a direct bond, or a defined linking group and R2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; together with processes for their preparation, pharmaceutical compositions containing them and their use as medicaments.Type: ApplicationFiled: June 4, 2007Publication date: August 20, 2009Inventors: Roger John Butlin, Robert Davies, William McCoull
-
Publication number: 20090197926Abstract: Compounds of formula (I), or salts thereof, which inhibit acetyl CoA (acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, wherein: R1 is selected from optionally substituted phenyl, cyclopentyl, cyclohexyl and 5- or 6-membered heteroaryl; L1 is a direct bond or a linker selected from, for example, —O—, —OCH2— and —CH2O—; R2 is selected from, for example, (3-6C)cycloalkyl, (5-12C)bicycloalkyl, phenyl and a 4, 5- or 6-membered saturated, partially or fully unsaturated heterocyclyl ring; wherein R2 is substituted by defined substituents and R6 is selected from, for example, hydrogen, fluoro and chloro; together with processes for their preparation, pharmaceutical compositions containing them and their use as medicaments.Type: ApplicationFiled: June 6, 2007Publication date: August 6, 2009Inventors: Alan Martin Birch, Roger John Butlin, Alleyn Thomas Plowright
-
Publication number: 20090186870Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.Type: ApplicationFiled: October 9, 2008Publication date: July 23, 2009Applicant: AstraZeneca ABInventors: Jack McQueen ALLEN, Roger John Butlin, Clive Green, William McCoull, Graeme Richard Robb, James Matthew Wood
-
Publication number: 20090118332Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as Fatty Acid Synthase inhibitors, methods for their therapeutic use, particularly in the treatment of obesity, diabetes mellitus, cancer and infection and pharmaceutical compositions containing them.Type: ApplicationFiled: December 20, 2007Publication date: May 7, 2009Applicant: AstraZeneca ABInventors: Roger John Butlin, Peter William Rodney Caulkett, Andrew Leach, Nicholas John Newcombe, Charles John O'Donnell, James Matthew Wood
-
Publication number: 20090105305Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as Fatty Acid Synthase inhibitors, methods for their therapeutic use, particularly in the treatment of obesity and diabetes mellitus, cancer and infection and pharmaceutical compositions containing them.Type: ApplicationFiled: December 20, 2007Publication date: April 23, 2009Applicant: AstraZeneca ABInventors: Roger John Butlin, Peter William Rodney Caulkett, Petra Johannesson, Laurent Daniel Knerr, Andrew Leach, Nicholas John Newcombe, Charles John O'Donnell, Helen Pointon, James Matthew Wood
-
Publication number: 20080161565Abstract: Process for preparing compounds of Formula (I); and (IV); are described.Type: ApplicationFiled: February 17, 2005Publication date: July 3, 2008Applicant: ASTRAZENECA ABInventors: Margaret Anne Butlin, Roger John Butlin, Philip John Hogan, Andreas Meudt
-
Patent number: 6878712Abstract: A compound of formula (I): wherein: Ring A is a nitrogen linked mono or bicyclic heterocyclic ring as defined within; R1 and R2 are independently C1-3alkyl optionally substituted by fluoro or chloro; or R1 and R2 together with the carbon atom to which they are attached, form a C3-5cycloalkyl ring optionally substituted by fluoro; R3 is defined within; and n is 0-5; wherein the values of R3 may be the same or different; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. The use of compounds of formula (I) in the production of an elevation of PDH activity in a warm-blooded animal such as a human being are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.Type: GrantFiled: August 30, 2000Date of Patent: April 12, 2005Assignee: AstraZeneca ABInventors: Roger John Butlin, Janet Elizabeth Pease, Michael Howard Block, Thorsten Nowak, Jeremy Nicholas Burrows, David Stephen Clarke
-
Patent number: 6689909Abstract: A compound of formula (I) wherein: n is 1 or 2; R1 is chloro, fluoro, bromo, methyl or methoxy; R2 is as defined within; R3 is as defined within; and R4 is hydrogen or fluoro; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. The use of compounds of formula (I) in the production of an elevation of PDH activity in a warm-blooded animal such as a human being are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.Type: GrantFiled: June 17, 2002Date of Patent: February 10, 2004Assignee: AstraZeneca ABInventors: Roger John Butlin, Janet Elizabeth Pease, Michael Howard Block, Thorsten Nowak, Jeremy Nicholas Burrows
-
Patent number: 6552225Abstract: A compound of formula (I) wherein: R1, R2, R3, R4, R5, R6 and R7 are as defined within; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. The use of compounds of formula (I) in the production of an elevation of PDH activity in a warm-blooded animal such as a human being are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.Type: GrantFiled: June 17, 2002Date of Patent: April 22, 2003Assignee: AstraZeneca ABInventors: Roger John Butlin, Janet Elizabeth Pease, Michael Howard Block, Thorsten Nowak, Jeremy Nicholas Burrows
-
Patent number: 6258817Abstract: The invention concerns pharmaceutically useful compounds of the formula I, in which A1, A2, A3, A4, B1, m, Ar, W, X, Y, Z and R1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.Type: GrantFiled: February 15, 2000Date of Patent: July 10, 2001Assignee: Zeneca Ltd.Inventors: Robert Hugh Bradbury, Roger John Butlin, Roger James
-
Patent number: 6060475Abstract: The invention concerns pharmaceutically useful compounds of the formula I, in which A.sup.1, A.sup.2, A.sup.3, A.sup.4, B.sup.1, m, Ar, W, X, Y, Z and R.sup.1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.Type: GrantFiled: December 14, 1998Date of Patent: May 9, 2000Assignee: Zeneca LimitedInventors: Robert Hugh Bradbury, Roger John Butlin, Roger James
-
Patent number: 5866568Abstract: The invention concerns pharmaceutically useful compounds of the formula I, in which A.sup.1, A.sup.2, A.sup.3, A.sup.4, B.sup.1, m, Ar, W, X, Y, Z and R.sup.1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.Type: GrantFiled: June 4, 1996Date of Patent: February 2, 1999Assignee: Zeneca LimitedInventors: Robert Hugh Bradbury, Roger John Butlin, Roger James